The celebrity prostate cancer line-up … and what they actually say

What celebs say and don’t say about prostate cancer (if they say anything at all) has often been difficult for the average patient to understand — as are some of their apparent treatment decisions (if those are actually mentioned). … READ MORE …

Moving targets and the interpretation of “new” medical “knowledge”

In this week’s New England Journal of Medicine (NEJM), there is an interesting article entitled, “Contingent knowledge and looping effects — a 66-year-old man with PSA-detected prostate cancer and regrets”. … READ MORE …

Cabazitaxel + carboplatin in treatment of mCRPC

A newly published article in Lancet Oncology has suggested that “taxane–platinum combinations have a clinically beneficial role in advanced prostate cancer”. … READ MORE …

FDA approves apalutamide for treatment of mCSPC here in US

Yesterday (September 17, 2019), the US Food and Drug Administration approved apalutamide (Erleada) for treatment of men with metastatic castration-sensitive prostate cancer (mCSPC) … READ MORE …

SABR to oligometastases slows progression via immune response

Stereotactic ablative body radiation (SABR, or sometimes, SBRT) significantly slowed metastatic progression in men with three or fewer metastases (oligometastatic disease). … READ MORE …

Complementary and alternative medicines in management of prostate cancer

A newly published paper in the Journal of Urology has reported on the use of complementary and alternative medicines (CAMs) among a cohort of nearly 8,000 American patients with a diagnosis of prostate cancer between 1996 and 2016. … READ MORE …

PCaI extends low-cost room rate for conference in Virginia Beach

Prostate Cancer International (PCaI) has been able extend the hotel discount deadline to Monday, Oct 7th for its FREE patient conference in Virginia Beach on November 2. … READ MORE …

High-dose vitamin D: negative results from a randomized clinical trial

Data from a recently published, Canadian, clinical trial of high-dose vitamin D as a method to strengthen bones in healthy adults who do not have osteoporesis have had significant and unexpectedly negative results. … READ MORE …

The APCCC in Basel, Switzerland: Day 3

So today, the third day of the meeting, was “voting day” on a total of 123 questions carefully crafted by the organizers prior to the meeting. The questions had all gone through three cycles of review and revision prior to the meeting. … READ MORE …

The APCCC in Basel, Switzerland: Day 2

The second day of the APCCC here in Basel ran for 10 hours and encompassed a total of six sessions, as follows: … READ MORE …

The APCCC in Basel, Switzerland: Day 1

So in this series of reports on what happened at the 3rd Advanced Prostate Cancer Consensus Conference (APCCC) in Basel, Switzerland, we will not be trying to get into detail about exactly what data got presented each day. … READ MORE …

Adjuvant chemotherapy does NOT improve BDFS rates in men with intermediate- and high-risk prostate cancer

With the third Advanced Prostate Cancer Consensus Conference (APCCC) due to start here in Basel, Switzerland, this morning, there is an important new set of data that will help to inform some of the discussions. … READ MORE …

FDA approves new technique for “ablation of prostate tissue”

According to a media release issued by a Canadian company called Profound Medical on August 16, the US Food and Drug Administration (FDA) has approved the use of a system called TULSA-PRO for the “ablation of prostate tissue”. There appears to be no relevant information on the FDA web site — as yet. … READ MORE …

The definition of a SECOND biochemical recurrence (after prostatectomy AND salvage radiation)

There is no standard definition of SECOND biochemical (PSA-detected) recurrence (BCR); that is, recurrence after both prostatectomy and salvage radiation (SRT). … READ MORE …

PARP inhibitor has positive outcomes in Phase III trial in selected men with mCRPC

According to a media release issued jointly yesterday by AstraZeneca and Merck, treatment with the PARP inhibitor olaparib (Lynparza) has demonstrated “positive results from the Phase III PROfound trial … in [a subset of] men with metastatic castration-resistant prostate cancer (mCRPC).” … READ MORE …